Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C

Hepatology

Volumn 32, Issue 3, 2000, Pages 630-634

  Brillanti, Stefano ^a   Levantesi, Fabio ^b   Masi, Livia ^a   Foli, Mauro ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale di Bentivoglio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; AMANTADINE; ANTIVIRUS AGENT; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEMOLYSIS; HEPATITIS C; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033839967     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.16235     Document Type: Article

References (24)

1. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
2. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
3. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
4. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C
5. New treatment strategies in non-responder patients with chronic hepatitis C
6. Amantadine for influenza A
7. Treatment of chronic hepatitis C with amantadine
8. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients
9. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy
10. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders
11. Serological determination of hepatitis C virus genotype: Comparison with a standardized genotyping assay
12. Classification of chronic hepatitis: Diagnosis, grading and staging
13. Standards of treatment in chronic hepatitis C
14. Consensus Statement. European Association for the Study of the Liver
15. The effect of amantadine on mouse hepatitis virus replication
16. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus
17. Combination antiviral therapy for respiratory virus infections
18. Randomized, double blind, placebo-controlled trial of interferon-alfa with and without amantadine as initial treatment for chronic hepatitis C
19. Interferon alfa2b-ribavirin vs. interferon alfa2b-ammantadine combination in chronic hepatitis C: Analyses of a randomized, double blind trial
20. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation
21. In vitro effect of amantadine and interferon alfa-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus infected patients
22. Effects of amantadine treatment on in vitro production of inter-leukin-2 in de-novo patients with idiopathic Parkinson's disease
23. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon-alfa-resistant chronic hepatitis C